- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05318027
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
Use of Natural Language Processing ChatBot and Automated Continuous Activity Monitoring Via Mobile Phones for Early Detection and Management of Symptoms in Patients Undergoing Cancer Treatment
Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits
Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michell Kim
- Phone Number: 215-760-2487
- Email: Michell.Kim@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Abramson Cancer Center of the University of Pennsylvania
-
Contact:
- Arun Goel, MD
- Phone Number: 215-662-6059
- Email: Arun.Goel@pennmedicine.upenn.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults (age >18 years) with a diagnosis of a head and neck, lung, gastrointestinal cancer, that are receiving concurrent chemotherapy and radiation treatment.
- Possession of a mobile device that can receive SMS texts and can deliver FitBit data wirelessly
- Ability read and respond in English
- Ability to provide informed consent to participate in the study
Exclusion Criteria:
- Patients who are bed bound at baseline (ECOG 4)
- Patients who rely on a wheelchair for ambulation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Activity Monitoring and ChatBot
Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring and utilize a ChatBot
|
The automated chatbot will check in with the patient on two pre-specified days between scheduled outpatient visits.
The chatbot will follow pre-specified symptom algorithms and classify symptoms as requiring high, intermediate and low risk follow ups.
High risk symptoms will trigger a same day nursing/physician visit or telemedicine call/video.
Intermediate risk symptoms will trigger a nursing triage visit or telemedicine call/video on the next day or treatment day.
Low risk symptoms will notify the treating physician to address the symptoms at the next scheduled on treatment visit (OTV).
If adjustments are needed in the chat bot triage algorithms, they will be updated in real time to decrease risk for adverse patient events.
|
No Intervention: Activity Monitoring without ChatBot
Patients will receive standard of care chemotherapy and radiation therapy regimens, activity monitoring alone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of triage visits
Time Frame: 13 weeks
|
Difference between Poisson event rates of triage visits between intervention and control arms
|
13 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Count of unplanned inpatient hospitalization
Time Frame: 13 weeks
|
13 weeks
|
Count of treatment breaks
Time Frame: 13 weeks
|
13 weeks
|
Count of emergency department visits
Time Frame: 13 weeks
|
13 weeks
|
Quality of Life scores
Time Frame: 13 weeks
|
13 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Arun Goel, MD, University of Pennsylvania
- Principal Investigator: Kristine Kim, MD, University of Pennsylvania
- Principal Investigator: Nishant Shah, MD, University of Pennsylvania
Publications and helpful links
General Publications
- McNeely ML, Campbell KL, Rowe BH, Klassen TP, Mackey JR, Courneya KS. Effects of exercise on breast cancer patients and survivors: a systematic review and meta-analysis. CMAJ. 2006 Jul 4;175(1):34-41. doi: 10.1503/cmaj.051073.
- Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29.
- Haj Mohammad N, Hulshof MC, Bergman JJ, Geijsen D, Wilmink JW, van Berge Henegouwen MI, van Laarhoven HW. Acute toxicity of definitive chemoradiation in patients with inoperable or irresectable esophageal carcinoma. BMC Cancer. 2014 Jan 31;14:56. doi: 10.1186/1471-2407-14-56.
- Waddle MR, Chen RC, Arastu NH, Green RL, Jackson M, Qaqish BF, Camporeale J, Collichio FA, Marks LB. Unanticipated hospital admissions during or soon after radiation therapy: Incidence and predictive factors. Pract Radiat Oncol. 2015 May-Jun;5(3):e245-e253. doi: 10.1016/j.prro.2014.08.004. Epub 2014 Sep 17.
- Lang K, Sussman M, Friedman M, Su J, Kan HJ, Mauro D, Tafesse E, Menzin J. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2009 Jun;135(6):582-8. doi: 10.1001/archoto.2009.46.
- Beg MS, Gupta A, Stewart T, Rethorst CD. Promise of Wearable Physical Activity Monitors in Oncology Practice. J Oncol Pract. 2017 Feb;13(2):82-89. doi: 10.1200/JOP.2016.016857.
- Uyterlinde W. Overcoming toxicity-challenges in chemoradiation for non-small cell lung cancer. Transl Lung Cancer Res. 2016 Jun;5(3):239-43. doi: 10.21037/tlcr.2016.05.03.
- Ghosh S, Rao PB, Kumar PR, Manam S. Concurrent Chemoradiation with Weekly Cisplatin for the Treatment of Head and Neck Cancers: an Institutional Study on Acute Toxicity and Response to Treatment. Asian Pac J Cancer Prev. 2015;16(16):7331-5. doi: 10.7314/apjcp.2015.16.16.7331.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UPCC 18921
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on ChatBot
-
Yonsei UniversityCompletedBreast NeoplasmsKorea, Republic of
-
University of Maryland, College ParkCompletedCervical Cancer | Anal Cancer | Penile CancerUnited States
-
Weill Medical College of Cornell UniversityRecruitingGynecologic Cancer | Hereditary Cancer SyndromeUnited States
-
Sun Yat-sen UniversityRecruiting
-
Cheng-Hsin General HospitalRecruitingLower Urinary Tract Symptoms | Erectile Dysfunction | Benign Prostate EnlargementTaiwan
-
Adonis Hijaz, MDRecruiting
-
University of Social Sciences and Humanities, WarsawMinistry of Science and Higher Education, PolandCompletedDepression | AnxietyPoland
-
University Hospital, ToulouseNot yet recruiting
-
University of ChicagoNorthShore University HealthSystemCompletedDepression, Postpartum | Depression, UnipolarUnited States
-
University of DelawareRecruitingInsomnia | Metabolic Syndrome | Sleep DeprivationUnited States